GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Endologix Inc (OTCPK:ELGXQ) » Definitions » Liabilities-to-Assets

Endologix (Endologix) Liabilities-to-Assets : 0.90 (As of Jun. 2020)


View and export this data going back to 1996. Start your Free Trial

What is Endologix Liabilities-to-Assets?

Liabilities-to-Assets is a solvency ratio indicating how much of the company’s assets are made of liabilities, calculated as total liabilities divided by total asset. Endologix's Total Liabilities for the quarter that ended in Jun. 2020 was $243.0 Mil. Endologix's Total Assets for the quarter that ended in Jun. 2020 was $271.4 Mil. Therefore, Endologix's Liabilities-to-Assets Ratio for the quarter that ended in Jun. 2020 was 0.90.


Endologix Liabilities-to-Assets Historical Data

The historical data trend for Endologix's Liabilities-to-Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Endologix Liabilities-to-Assets Chart

Endologix Annual Data
Trend Dec10 Dec11 Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19
Liabilities-to-Assets
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.69 0.69 0.79 0.87 0.79

Endologix Quarterly Data
Sep15 Dec15 Mar16 Jun16 Sep16 Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20
Liabilities-to-Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.78 0.78 0.79 0.82 0.90

Competitive Comparison of Endologix's Liabilities-to-Assets

For the Medical Instruments & Supplies subindustry, Endologix's Liabilities-to-Assets, along with its competitors' market caps and Liabilities-to-Assets data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Endologix's Liabilities-to-Assets Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Endologix's Liabilities-to-Assets distribution charts can be found below:

* The bar in red indicates where Endologix's Liabilities-to-Assets falls into.



Endologix Liabilities-to-Assets Calculation

Liabilities-to-Assets ratio measures the portion of the total liabilities to the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.

Liabilities-to-Assets ratio is calculated by dividing total liabilities by total asset.

Endologix's Liabilities-to-Assets Ratio for the fiscal year that ended in Dec. 2019 is calculated as:

Liabilities-to-Assets (A: Dec. 2019 )=Total Liabilities/Total Assets
=243.308/307.164
=0.79

Endologix's Liabilities-to-Assets Ratio for the quarter that ended in Jun. 2020 is calculated as

Liabilities-to-Assets (Q: Jun. 2020 )=Total Liabilities/Total Assets
=242.998/271.415
=0.90

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Endologix  (OTCPK:ELGXQ) Liabilities-to-Assets Explanation

Liabilities-to-Assets is a solvency ratio indicating how much of the company’s assets are made of liabilities. It can vary greatly across different industries, as they have different capital structure. A high Liabilities-to-Assets ratio (more leveraged) suggests that the company might have potential solvency problems, or even a signal of financial distress. Conversely, a low Liabilities-to-Assets ratio usually indicates a healthy financial situation. However, it may also suggest that the company is not expanding or not making good use of debt.


Endologix Liabilities-to-Assets Related Terms

Thank you for viewing the detailed overview of Endologix's Liabilities-to-Assets provided by GuruFocus.com. Please click on the following links to see related term pages.


Endologix (Endologix) Business Description

Traded in Other Exchanges
N/A
Address
2 Musick, Irvine, CA, USA, 92618
Endologix Inc develops, manufacture, market, and sell innovative medical devices for the treatment of aortic disorders in the United States and internationally. The company only reporting segment that is focused on the development, manufacture, marketing, and sale of EVAR and EVAS products for the treatment of aortic disorders. It product Includes a variety of endovascular stent grafts for the treatment of abdominal aortic aneurysms such as AFX Endovascular AAA System, VELA Proximal Endograft, and Ovation Abdominal Stent Graft System. The firm generates the majority of its revenue in the United States.
Executives
Dan Lemaitre director 2 MUSICK, IRVINE CA 92618
Gregory D Waller director 1717 W COLLINS AVENUE, ORANGE CA 92867
John Onopchenko director, officer: CEO and Director C/O VOLCANO CORPORATION 11455 EL CAMINO REAL, SUITE 460 SAN DIEGO CA 92130
Thomas Wilder director 2 MUSICK, IRVINE CA 92618
Matthew Thompson officer: Chief Medical Officer 2 MUSICK, IRVINE CA 92618
Timothy Nicholas Brady officer: Controller and Corp Secretary 2 MUSICK IRVINE CA 92618
Cynthia Buch Pinto officer: Interim CFO 2 MUSICK IRVINE CA 92618
Jeff Fecho officer: Chief Quality Officer ONE ST. JUDE MEDICAL DRIVE ST. PAUL MN 55117
Richard W Mott director 1221 CROSSMAN AVENUE, SUNNYVALE CA 94089
Vaseem Mahboob officer: Chief Financial Officer 2 MUSICK IRVINE CA 92618
Jane E Kiernan director 525 W ROSCOE, CHICAGO IL 60657
John Zehren officer: Chief Commercial Officer 2 MUSICK IRVINE CA 92618
Jeremy B. Hayden officer: General Counsel 2 MUSICK, 2 MUSICK, IRVINE CA 92618
Leslie V Norwalk director C/O 3661 VALLEY CENTRE DRIVE SUITE 200, SAN DIEGO CA 92130
Zenty Iii Thomas F director 2 MUSICK IRVINE CA 92618